LUZP1 and prostate carcinoma: In line with the genomic analysis and the gene dosage-mRNA expression association, using Cancertool (Cortazar et al., 2018) we found the mRNA levels of LUZP1 to be significantly reduced in prostate cancer (Figures 1F,G), and non-significantly in breast cancer (Figure 1E).